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Herpes  simplex  virus  (HSV)-based  vectors  have  been  used  as
platforms  for  the  generation  of  genetic  vaccines  against  dif-
ferent  viruses.  Some  of  the  advantages  of  defective  HSV-1
vectors  include:  (a)  HSV-1  can  infect  most  cell  types,  includ-
ing  antigen-presenting  cells;  (b)  HSV-1  vectors  have  a  large
transgene  capacity  (up  to  150-kbp);  (c)  HSV-1  vectors  can  be
designed  to  cause  no  toxicity;  (d)  different  studies  showed
that  mice  vaccinated  with  such  vectors  encoding  antigens
from  different  pathogens  were  partially  protected1,3,  indi-
cating  that  HSV-1  based  vectors  are  attractive  tools  for  the
development  of  safe  genetic  vaccines.
There  are  two  main  platforms  of  HSV-1-derived  vectors:
defective  recombinant  viruses  (deleted  in  ICP4,  ICP27  and
ICP22  genes)  and  amplicons.  Defective  HSV-1  viruses  can
only  be  propagated  using  a  complementing  cell  line.  Pro-
duction  of  amplicons  depends  on  helper  functions,  provided
in  trans. In  both  systems,  different  genetic  elements  were
intentionally  introduced  to  conduct  the  heterologous  gene
expression  and  to  allow  the  titration  of  the  vector  stocks  in
different  cell  lines2,4.
In  our  group,  HSV-1  vectors  were  developed  for  the
expression  of  several  rotavirus  genes.  Genes  from  other
pathogens  were  also  expressed,  thus  generating  a  set  of
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tools  to  be  tested  as  new  vaccine  candidates  against  dif-
ferent  diseases.
In  this  section,  we  show  two  different  HSV-1  vectors  that
express  the  VP6  protein  from  different  rotavirus  strains.
Figure  1  shows  a  defective  recombinant  virus  expressing
simultaneously  Enhanced  Green  Fluorescent  Protein  (EGFP)
and  VP6  from  murine  rotavirus  strain  EC,  in  Figure  2  and
movie  S1,  an  amplicon  vector  overexpressing  VP6  from  a
Wa  strain  of  human  rotavirus  is  shown.  In  both  cases,  the
VP6  proteins  were  recognized  by  a  monoclonal  antibody
and  were  found  extensively  expressed  forming  ﬁlaments
along  the  cells,  showing  a  typical  intra-cellular  pattern,  in
the  absence  of  other  rotavirus  protein.  These  results  show
that  the  recombinant  proteins  maintain  the  speciﬁc  capac-
ity  of  self-assembly  of  the  native  protein  and,  therefore,
are  potential  vaccine  candidates  to  be  explored.  Recently,
results  obtained  by  our  group  and  in  collaboration  with  oth-
ers,  have  demonstrated  the  feasibility  of  these  systems  to
induce  protective  immune  responses  against  different  viral
infections1,3.
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Figure  1  MDBK  cells  were  transduced  with  T0EC-VP6  recom-
binant  vector.  Permeabilized  cells  were  probed  with  monoclonal
antibody  (MAb)  2F,  directed  against  the  UK  strain  rotavirus
VP6, followed  by  Alexa-594  anti-mouse  antibody  (Molecular
Probes,  USA).  Nuclear  DNA  was  stained  with  4′,6,-Diamidino-
2-Phenylindole,  Invitrogen  (DAPI).  Wa-VP6  and  EGFP  expression
were observed  under  the  microscope  and  the  obtained  images
were merged  into  the  same  picture.  Bar,  20  m.
Figure  2  Vero  cells  were  transduced  with  HSV  [Wa-VP6]
amplicon  vector.  Permeabilized  cells  were  probed  with  MAb
2F, followed  by  Alexa-594  anti-mouse  antibody  (Molecular
Probes,  USA).  Nuclear  DNA  was  stained  with  4′,6,-Diamidino-
2-Phenylindole,  Invitrogen  (DAPI).  Wa-VP6  and  EGFP  expression
were observed  under  the  microscope,  and  the  obtained  images
were  merged  into  the  same  picture.  The  bar  indicates  20  m.
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